Privi Speciality Chemicals Reports 24.6% Growth in Q2 FY27 Net Profit

manufacturing-news
Mahesh Babani, Chairman & Managing Director

Privi Speciality Chemicals Limited reported higher revenue and profit for the quarter ended September 30, 2026, supported by demand across domestic and international markets and improved manufacturing efficiencies. Consolidated total income for Q2 FY27 increased 13.90% year-on-year to ₹773.16 crore, while EBITDA rose 16.66% to ₹212.49 crore.

Profit after tax attributable to the company grew 24.61% to ₹117.03 crore. Earnings per share stood at ₹29.96, compared with ₹24.04 in the corresponding quarter of the previous financial year. EBITDA margin improved by 65 basis points to 27.48%. For the first half of FY27, Privi recorded total income of ₹1,454.59 crore, an increase of 16.7% over the same period last year. EBITDA grew 17.6% to ₹379.96 crore, while profit after tax attributable to the company rose 29.1% to ₹201.23 crore. The H1 EBITDA margin stood at 26.12%, compared with 25.92% a year earlier.

The company reported a return on capital employed of 24.30% and return on equity of 26.34% as of September 30, 2026. Its net debt-to-EBITDA ratio improved to 1.07 times, a 32.1% year-on-year improvement. Net cash generated from operating activities during the first half amounted to ₹360.26 crore.

Privi operates seven manufacturing facilities with an installed production capacity of 48,000 tonnes per annum. Its backward-integrated operations include in-house CST processing capabilities, which support raw material management and production efficiency. The company is also investing in capacity expansion, process improvements and product development.

Expansion projects are progressing according to schedule and are expected to be ready for commercial operations in the second half of 2028. The company’s development pipeline includes Maltol and Ethyl Maltol, Renewable Cyclopentanone, Furfural and more than 10 other speciality products. Its joint venture with Givaudan, PRIGIV, has a pipeline of more than 40 products. The proposed amalgamation of Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited with Privi Speciality Chemicals is expected to add green chemistry and biotechnology capabilities to its operations.

Chairman and Managing Director Mahesh Babani said the company had maintained the momentum established in the first quarter. He attributed the performance to its integrated manufacturing operations and focus on cost and operational efficiency. He added that the company remained on track to achieve its 5K:1K target of ₹5,000 crore in revenue and more than ₹1,000 crore in EBITDA by FY30.

Privi Speciality Chemicals (BSE: 530117; NSE: PRIVISCL) manufactures and exports aroma chemicals for global fragrance, flavour and FMCG companies. Its operations focus on integrated manufacturing, product development, quality and regulatory compliance.